Intravitreal Bevacizumab for Neovascular Glaucoma (IVB NVG)

Shahid Beheshti University of Medical Sciences

Status: Completed

Conditions: Neovascular; Glaucoma

Treatments: Other: subconjunctival normal saline; Drug: Avastin

Study type: Interventional

Funder types: Other

Identifiers

NCT00384631

8414

Details and patient eligibility

About

Several studies have confirmed high levels of vascular endothelial growth factor (VEGF) in eyes with neovascular glaucoma (NVG). The role of VEGF inhibitors in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic macular edema has been described. We aim to evaluate the effect of three intravitreal injections of bevacizumab (Avastin) 2.5 mg versus a sham procedure for treatment of NVG. Outcome measures include intraocular pressure and extent of iris neovascularization. Both study arms will receive conventional treatment for NVG.

Enrollment: 26 patients

Sex: All

Ages: 10 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of NVG
• Vision less than 20/200
• age 10-80 years

Exclusion criteria

• Uncontrolled Blood Pressure
• History of thromboembolism
• Congestive Heart Failure
• Renal Failure
• Pregnancy or Lactation
• Active ocular or periocular infection
• No light perception

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

26 participants in 2 patient groups

2

Sham Comparator group

Treatment:

Other: subconjunctival normal saline

1

Experimental group

Treatment:

Drug: Avastin